Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Remogliflozin etabonate · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Hydrochlorothiazide (HCTZ) | DRUG | - |
| Remogliflozin etabonate (GSK189075) | DRUG | - |
| Furosemide | DRUG | - |
Inclusion Criteria: * Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range...
Remogliflozin etabonate is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is a metabolic therapeutic agent that has been studied in clinical trials, though it is not yet approved and remains in early-stage development.
Remogliflozin etabonate is being developed by GSK plc, which trades under the ticker GSK. The company has conducted clinical research on this drug candidate for Type 2 Diabetes Mellitus.
Remogliflozin etabonate is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug is not currently in active clinical trials.
Remogliflozin etabonate has been studied in one completed Phase 1 trial, NCT00671424, titled 'A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide.' The trial enrolled 48 male participants in the United States and included healthy volunteers.
Remogliflozin etabonate is also known as GSK189075. In clinical trial NCT00671424, the drug is referred to as GSK189075, confirming that these names refer to the same investigational compound.